This page was translated automatically from Turkish. Read the original

Bu sayfa, 26. Dünya Psikiyatri Kongresi'nde sunulan çalışmanın yapay zekâ desteğiyle hazırlanmış Türkçe özetidir. Çalışmanın sahibi sunan yazarlardır; atıf için orijinal kaynağa başvurun.

EV0369

Metabolic syndrome in schizophrenia: a bibliometric analysis

METABOLIC SYNDROME IN SCHIZOPHRENIA: A BIBLIOMETRIC ANALYSIS

The literature on metabolic syndrome in schizophrenia has reached maturity with 2,734 documents, and the field’s focus should shift from risk characterization to clinical trials aimed at mitigating pharmacological risk.

Cardiovascular disease is the leading cause of death in schizophrenia and is associated with an average of 14.5 years of potential life lost. This gap is largely attributed to the high prevalence of metabolic syndrome in this population, reported to range from 32.5% to 41.3%; this study aimed to map the intellectual, conceptual, and social structure of global scientific output in this field using bibliometric techniques. Records retrieved from the Web of Science Core Collection database using a Boolean search strategy were cleaned and normalized in R, yielding a final sample of 2,734 documents. Network topology characteristics and conceptual structures were analyzed using Biblioshiny and VOSviewer, and author keyword co-occurrences were normalized using a custom thesaurus file. Scientific output has reached maturity, accounting for 72.9% of the projected saturation level (K = 3,748 publications), and the annual growth trend fits the logistic model very well (R² = 0.922); historical output peaked in 2020 (172 publications/year). According to Bradford’s law, the core journals driving the field were identified as Schizophrenia Research, Psychiatry Research, and Frontiers in Psychiatry. The keyword co-occurrence network revealed three thematic clusters: a red cluster encompassing epidemiological parameters, prevalence data, and cardiovascular comorbidities; a green cluster covering antipsychotic-associated metabolic risks, second-generation agents (clozapine, olanzapine, risperidone), and clinical trials; and a blue cluster encompassing anthropometric measurements (body mass index). Geographically, China, the United States, the United Kingdom, Australia, and France lead research in the field, with dense interinstitutional collaboration networks. The authors state that the metabolic risk associated with second-generation antipsychotics is now well established and that, to reduce cardiovascular morbidity, the field should shift toward clinical trials aimed at mitigating pharmacological risk and toward active management.

Tüm WCP 2026 özetleri